0.4247

9.18% 0.0357

After Hours: .42 -0.0047 -1.11%

Fibrogen Inc (FGEN)

Overview News Price History Option Chain Financials Why FGEN Down? Discussions Forecast

Fibrogen Inc stock is traded at $0.4247, with a volume of 1.09M. It is up +9.18% in the last 24 hours and up +38.70% over the past month. FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

Previous Close:

$0.389

Open:

$0.3965

24h Volume:

1.09M

Relative Volume:

0.92

Market Cap:

$42.80M

Revenue:

$147.75M

Net Income/Loss:

$-284.23M

P/E Ratio:

-0.1253

EPS:

-3.39

Net Cash Flow:

$-317.54M

1W Performance:

+7.41%

1M Performance:

+38.70%

6M Performance:

-63.70%

1Y Performance:

-14.82%

1-Day Range:

$0.3813

$0.4331

1-Week Range:

$0.3761

$0.4331

52-Week Range:

$0.18

$2.93

Fibrogen Inc Stock (FGEN) Company Profile

Name

Fibrogen Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

415-978-1200

Address

350 BAY STREET, SAN FRANCISCO, CA

Employee

486

Twitter

@FibroGenInc

Next Earnings Date

2024-11-04

Latest SEC Filings

FGEN's Discussions on Twitter

Compare FGEN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FGEN Fibrogen Inc	0.4247	42.80M	147.75M	-284.23M	-317.54M	-2.93
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Fibrogen Inc Stock (FGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-08-23	Downgrade	BofA Securities	Neutral → Underperform
Jun-26-23	Downgrade	BofA Securities	Buy → Neutral
Jun-26-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jun-26-23	Downgrade	Stifel	Buy → Hold
Jun-26-23	Downgrade	William Blair	Outperform → Mkt Perform
Jun-02-23	Upgrade	Stifel	Hold → Buy
Jan-31-23	Upgrade	William Blair	Mkt Perform → Outperform
Jan-26-23	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-05-23	Upgrade	BofA Securities	Neutral → Buy
Sep-22-21	Downgrade	Goldman	Neutral → Sell
Aug-20-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-16-21	Downgrade	BofA Securities	Buy → Neutral
Jul-16-21	Downgrade	Stifel	Buy → Hold
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-07-21	Downgrade	Mizuho	Buy → Neutral
Mar-31-21	Upgrade	BofA Securities	Neutral → Buy
Mar-02-21	Downgrade	Jefferies	Buy → Hold
Feb-01-21	Initiated	H.C. Wainwright	Buy
Oct-26-20	Initiated	Raymond James	Underperform
Jul-10-20	Resumed	Stifel	Buy
May-01-20	Initiated	Cowen	Market Perform
Apr-27-20	Initiated	BofA/Merrill	Neutral
May-29-19	Resumed	Goldman	Neutral
May-10-19	Downgrade	William Blair	Outperform → Mkt Perform
Apr-12-19	Initiated	Piper Jaffray	Neutral
Feb-11-19	Resumed	Stifel	Buy
Dec-19-18	Upgrade	Citigroup	Neutral → Buy
Aug-08-17	Reiterated	Leerink Partners	Outperform
Aug-08-17	Reiterated	Stifel	Buy
Jul-21-17	Downgrade	Goldman	Buy → Neutral
Jul-11-17	Initiated	Jefferies	Buy
Feb-11-16	Upgrade	Credit Suisse	Neutral → Outperform
Jan-21-16	Initiated	Credit Suisse	Neutral
Dec-04-15	Initiated	Citigroup	Buy
Sep-23-15	Initiated	Lake Street	Hold
Jul-29-15	Initiated	Citigroup	Buy
Jul-20-15	Upgrade	Goldman	Neutral → Buy
Dec-09-14	Initiated	Stifel	Buy

View All

Fibrogen Inc Stock (FGEN) Latest News

Nov 28, 2024

FibroGen Inc earnings beat by $0.14, revenue topped estimates - Investing.com Nigeria

Nov 28, 2024

Nov 25, 2024

Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail

Nov 25, 2024

Nov 16, 2024

FGEN stock touches 52-week low at $0.19 amid market challenges - Investing.com India

Nov 14, 2024

Nov 13, 2024

FibroGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

FibroGen, Inc. (NASDAQ:FGEN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Earnings call: FibroGen reports strong Q3 sales, advances in oncology pipeline - Investing.com UK

Nov 13, 2024

FibroGen: Q3 Earnings Snapshot - mySA

Nov 13, 2024